• Search History (Register)
  • MeSH Browser
Sort by Relevance
Search Results [15895 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2021 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Neuromuscular feedback therapy for paraplegia]
2021 WorkSafeBC Causal association between care aide work and the development of carpal tunnel syndrome (CTS)
2021 WorkSafeBC Acupuncture or massage therapy as treatment for occipital neuralgia
2021 Malaysian Health Technology Assessment (MaHTAS) Platelet rich plasma, platele-rich fibrin (PRF) and concentrated growth factor (CGF) for treatment of periodontal disease
2021 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Key items for developing and implementing a high complexity/cost surgical implants registry for its postmarketing surveillance]
2021 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Nutritional therapy in heart failure patients with malnutrition]
2021 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Automated storage and dispensing medication systems in hospital pharmacy services. Safety, effectiveness and efficiency]
2021 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of mHealth-based technology for mobile applications]
2021 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Nutritional treatment of multi-morbid patients in a state of malnutrition]
2021 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Nutritional treatment of patients with chronic obstructive pulmonary disease in a state of malnutrition]
2021 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Safety, effectiveness and efficiency of glucometers, gasometers and coagulometers]
2021 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Platform to analyse RNA, DNA or proteins as biomarkers in the diagnosis, prognosis and assessment of treatments]
2021 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of the effectiveness of hip and knee implant models used by the Spanish National Health System]
2021 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Next-generation sequencing (NGS) for molecular diagnosis and the selection of therapeutic targets in oncology]
2021 Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Review of the evidence on the impact of school closures through the evolution of the COVID-19 pandemic]
2021 The Regional Health Technology Assessment Centre (HTA-centrum) Clinical effects of preoperative i.v. iron infusion in patients with colorectal cancer and iron-deficiency anemia
2021 The Regional Health Technology Assessment Centre (HTA-centrum) Clopidogrel versus ticagrelor as part of dual antiplatelet therapy for patients with acute coronary syndrome
2021 The Regional Health Technology Assessment Centre (HTA-centrum) Efficacy and safety of endovascular versus surgical arteriovenous fistula creation for hemodialysis
2021 The Regional Health Technology Assessment Centre (HTA-centrum) Effectiveness and safety of breast reduction surgery, compared with no surgery, in women with symptomatic breast hypertrophy
2021 National Institute for Health and Care Excellence (NICE) Encorafenib plus cetuximab for previously treated BRAF V600E mutation-positive metastatic colorectal cancer. NICE technology appraisal guidance 668
2021 National Institute for Health and Care Excellence (NICE) Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor. NICE technology appraisal guidance 670
2021 National Institute for Health and Care Excellence (NICE) Mepolizumab for treating severe eosinophilic asthma. NICE technology appraisal guidance 671
2021 National Institute for Health and Care Excellence (NICE) Brolucizumab for treating wet age-related macular degeneration. NICE technology appraisal guidance 672
2021 National Institute for Health and Care Excellence (NICE) Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 673
2021 National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal). NICE technology appraisal guidance 674
2021 National Institute for Health and Care Excellence (NICE) Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal). NICE technology appraisal guidance 675
2021 National Institute for Health and Care Excellence (NICE) Filgotinib for treating moderate to severe rheumatoid arthritis. NICE technology appraisal guidance 676
2021 National Institute for Health and Care Excellence (NICE) Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma. NICE technology appraisal guidance 677
2021 National Institute for Health and Care Excellence (NICE) Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal). NICE technology appraisal guidance 678
2021 National Institute for Health and Care Excellence (NICE) Dapagliflozin for treating chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 679
2021 National Institute for Health and Care Excellence (NICE) Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myeloma. NICE technology appraisal guidance 680
2021 National Institute for Health and Care Excellence (NICE) Baricitinib for treating moderate to severe atopic dermatitis. NICE technology appraisal guidance 681
2021 National Institute for Health and Care Excellence (NICE) Erenumab for preventing migraine. NICE technology appraisal guidance 682
2021 National Institute for Health and Care Excellence (NICE) Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer. NICE technology appraisal guidance 683
2021 National Institute for Health and Care Excellence (NICE) Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease. NICE technology appraisal guidance 684
2021 National Institute for Health and Care Excellence (NICE) Anakinra for treating Still's disease. NICE technology appraisal guidance 685
2021 National Institute for Health and Care Excellence (NICE) Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal). NICE technology appraisal guidance 686
2021 National Institute for Health and Care Excellence (NICE) Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 687
2021 National Institute for Health and Care Excellence (NICE) Selective internal radiation therapies for treating hepatocellular carcinoma. NICE technology appraisal guidance 688
2021 National Institute for Health and Care Excellence (NICE) Acalabrutinib for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 689
2021 National Institute for Health and Care Excellence (NICE) Avelumab for untreated metastatic Merkel cell carcinoma. NICE technology appraisal guidance 691
2021 National Institute for Health and Care Excellence (NICE) Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy. NICE technology appraisal guidance 692
2021 National Institute for Health and Care Excellence (NICE) Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer. NICE technology appraisal guidance 693
2021 National Institute for Health and Care Excellence (NICE) Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia. NICE technology appraisal guidance 694
2021 National Institute for Health and Care Excellence (NICE) Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myeloma. NICE technology appraisal guidance 695
2021 National Institute for Health and Care Excellence (NICE) Tafamidis for treating transthyretin amyloidosis with cardiomyopathy. NICE technology appraisal guidance 696
2021 National Institute for Health and Care Excellence (NICE) Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban. NICE technology appraisal guidance 697
2021 National Institute for Health and Care Excellence (NICE) Ravulizumab for treating paroxysmal nocturnal haemoglobinuria. NICE technology appraisal guidance 698
2021 National Institute for Health and Care Excellence (NICE) Ofatumumab for treating relapsing multiple sclerosis. NICE technology appraisal guidance 699
2021 National Institute for Health and Care Excellence (NICE) Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 700
2021 National Institute for Health and Care Excellence (NICE) Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal). NICE technology appraisal guidance 701
2021 National Institute for Health and Care Excellence (NICE) Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal). NICE technology appraisal guidance 702
2021 National Institute for Health and Care Excellence (NICE) Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal). NICE technology appraisal guidance 703
2021 National Institute for Health and Care Excellence (NICE) Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies. NICE technology appraisal guidance 704
2021 National Institute for Health and Care Excellence (NICE) Atezolizumab monotherapy for untreated advanced non-small-cell lung cancer. NICE technology appraisal guidance 705
2021 National Institute for Health and Care Excellence (NICE) Ozanimod for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 706
2021 National Institute for Health and Care Excellence (NICE) Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer. NICE technology appraisal guidance 707
2021 National Institute for Health and Care Excellence (NICE) Budesonide orodispersible tablet for inducing remission of eosinophilic oesophagitis. NICE technology appraisal guidance 708
2021 National Institute for Health and Care Excellence (NICE) Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 709
2021 National Institute for Health and Care Excellence (NICE) Ravulizumab for treating atypical haemolytic uraemic syndrome. NICE technology appraisal guidance 710
2021 National Institute for Health and Care Excellence (NICE) Enzalutamide for treating hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 712
2021 National Institute for Health and Care Excellence (NICE) Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy. NICE technology appraisal guidance 713
2021 National Institute for Health and Care Excellence (NICE) Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal). NICE technology appraisal guidance 714
2021 National Institute for Health and Care Excellence (NICE) Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed. NICE technology appraisal guidance 715
2021 National Institute for Health and Care Excellence (NICE) Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency. NICE technology appraisal guidance 716
2021 National Institute for Health and Care Excellence (NICE) Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal). NICE technology appraisal guidance 717
2021 National Institute for Health and Care Excellence (NICE) Ixekizumab for treating axial spondyloarthritis. NICE technology appraisal guidance 718
2021 National Institute for Health and Care Excellence (NICE) Secukinumab for treating non-radiographic axial spondyloarthritis. NICE technology appraisal guidance 719
2021 National Institute for Health and Care Excellence (NICE) Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma. NICE technology appraisal guidance 720
2021 National Institute for Health and Care Excellence (NICE) Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 721
2021 National Institute for Health and Care Excellence (NICE) Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement. NICE technology appraisal guidance 722
2021 National Institute for Health and Care Excellence (NICE) Bimekizumab for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 723
2021 National Institute for Health and Care Excellence (NICE) Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer. NICE technology appraisal guidance 724
2021 National Institute for Health and Care Excellence (NICE) Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 725
2021 National Institute for Health and Care Excellence (NICE) Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 726
2021 National Institute for Health and Care Excellence (NICE) Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal). NICE technology appraisal guidance 727
2021 National Institute for Health and Care Excellence (NICE) Midostaurin for treating advanced systemic mastocytosis. NICE technology appraisal guidance 728
2021 National Institute for Health and Care Excellence (NICE) Sapropterin for treating hyperphenylalaninaemia in phenylketonuria. NICE technology appraisal guidance 729
2021 National Institute for Health and Care Excellence (NICE) Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal). NICE technology appraisal guidance 730
2021 National Institute for Health and Care Excellence (NICE) Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal). NICE technology appraisal guidance 731
2021 National Institute for Health and Care Excellence (NICE) Baloxavir marboxil for treating acute uncomplicated influenza (terminated appraisal). NICE technology appraisal guidance 732
2021 National Institute for Health and Care Excellence (NICE) Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia. NICE technology appraisal guidance 733
2021 National Institute for Health and Care Excellence (NICE) Secukinumab for treating moderate to severe plaque psoriasis in children and young people. NICE technology appraisal guidance 734
2021 National Institute for Health and Care Excellence (NICE) Tofacitinib for treating juvenile idiopathic arthritis. NICE technology appraisal guidance 735
2021 National Institute for Health and Care Excellence (NICE) Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy. NICE technology appraisal guidance 736
2021 National Institute for Health and Care Excellence (NICE) Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer. NICE technology appraisal guidance 737
2021 National Institute for Health and Care Excellence (NICE) Berotralstat for preventing recurrent attacks of hereditary angioedema. NICE technology appraisal guidance 738
2021 National Institute for Health and Care Excellence (NICE) Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable. NICE technology appraisal guidance 739
2021 National Institute for Health and Care Excellence (NICE) Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer. NICE technology appraisal guidance 740
2021 National Institute for Health and Care Excellence (NICE) Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer. NICE technology appraisal guidance 741
2021 National Institute for Health and Care Excellence (NICE) Selpercatinib for treating advanced thyroid cancer with RET alterations. NICE technology appraisal guidance 742
2021 National Institute for Health and Care Excellence (NICE) Crizanlizumab for preventing sickle cell crises in sickle cell disease. NICE technology appraisal guidance 743
2021 National Institute for Health and Care Excellence (NICE) Upadacitinib for treating moderate rheumatoid arthritis. NICE technology appraisal guidance 744
2021 National Institute for Health and Care Excellence (NICE) NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal). NICE technology appraisal guidance 745
2021 National Institute for Health and Care Excellence (NICE) Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer. NICE technology appraisal guidance 746
2021 National Institute for Health and Care Excellence (NICE) Nintedanib for treating progressive fibrosing interstitial lung diseases. NICE technology appraisal guidance 747
2021 National Institute for Health and Care Excellence (NICE) Mexiletine for treating the symptoms of myotonia in non-dystrophic myotonic disorders. NICE technology appraisal guidance 748
2021 National Institute for Health and Care Excellence (NICE) Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal). NICE technology appraisal guidance 749
2021 National Institute for Health and Care Excellence (NICE) Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after platinum-based chemotherapy (terminated appraisal). NICE technology appraisal guidance 750
2021 National Institute for Health and Care Excellence (NICE) Dupilumab for treating severe asthma with type 2 inflammation. NICE technology appraisal guidance 751